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Introduction
Amiloidosis is most fatal complication of FMF. Former
studies recognize that endothelial functions were severely
impaired in patients who have amyloidosis than the
patients who have other glomerulopathies. Asymmetric
dimethyl arginine (ADMA), the endogenous inhibitor of
nitric oxide synthase is possibly a causative or predictive
factor in endothelial dysfunction in humans.
Objectives
Compare the amyloidosis group to only proteinuria group
for biochemical, demographic and some other features
such as flow-mediated dilation (FMD), to understand
which markers may affect or help prediction of amyloido-
sis. We also evaluated the effects of elevated ADMA levels
and impaired FMD responses on the survival time of CVD
free period in two distinct groups with severe proteinuria,
secondary amyloidosis (SA) versus primary glomerulopa-
thy. We proposed that increased ADMA synthesis in amy-
loidosis induced endothelial damage may contribute part
of the mechanism by which proteinuria increases cardio-
vascular morbidity and mortality.
Methods
Study was part of a cohort study. The amiloidosis and pro-
teiuria groups were followed up for predictive factors. All
enrolled subjects were evaluated by standard physical
examination, chest X-ray, baseline electrocardiogram, two-
dimensional echocardiography, and routine biochemical
laboratory tests, including liver and kidney function tests
and 24-hour urinary protein measurements. FMD and
venous blood samples were taken following a 2 week
wash-out period, during which time no vasoactive drugs
(including colchicines) were given. Measurements of
serum ADMA and SDMA were done using HPLC.
Results
The data of 102 patients with proteinuria due to primary
glomerulopathy and 98 patients with amyloidosis due to
FMF were assessed. Median age of diagnosis in patients
with amyloidosis was 16 (min.-max.: 6-25) and 71.4 % of
patients were 18 or younger at the date of diagnoses of
amyloidosis. Patients with amyloidosis provided higher
levels of SDMA and ADMA (p < 0.01) and lower FMD
percentage when compared to patients with glomerulone-
phritis (p < 0.01). Inflammatory markers such as high sen-
sitivity C-reactive protein (hsCRP) and pentraxim-3 were
statistically different between groups and higher among
patients with amyloidosis.
Conclusion
Inflammatory markers such as hsCRP and pentraxim-3
were statistically different between groups and higher
among patients with amyloidosis. The mortality and the
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